www.rtog.org 1

WELCOMEWELCOME

RTOGRTOG

RA OrientationRA Orientation

PhiladelphiaPhiladelphia

www.rtog.org 2

Established in 1968

Several International facilities participate in RTOG trials

United States United States KoreaKorea

CanadaCanada Saudi ArabiaSaudi Arabia FranceFrance IrelandIreland

IsraelIsraelAustraliaAustralia

NCI Funding and Corporate Support

RTOG BACKGROUNDRTOG BACKGROUND

www.rtog.org 3

RTOG BACKGROUNDRTOG BACKGROUND

Opened >400 ProtocolsOpened >400 Protocols

Enrolled 65,000 patients to its studiesEnrolled 65,000 patients to its studies

Published more than 700 papersPublished more than 700 papers

Maintains a roster of 40 active studies Maintains a roster of 40 active studies devoted to the group’s primary disease sitesdevoted to the group’s primary disease sites

www.rtog.org 4

RTOG PRIMARY DISEASE SITESRTOG PRIMARY DISEASE SITES

BRAINBRAIN

Head & NeckHead & Neck

LungLung

BreastBreast

www.rtog.org 5

RTOG PRIMARY DISEASE SITESRTOG PRIMARY DISEASE SITES

GYNGYN

GenitourinaryGenitourinaryBladderBladderProstateProstate

GastrointestinalGastrointestinalEsophagusEsophagusRectumRectumAnal CanalAnal CanalStomachStomach

PancreasPancreas

SarcomaSarcoma

www.rtog.org 6

MISSIONMISSION

Improve survival outcome and quality of life of adults withImprove survival outcome and quality of life of adults with cancercancer

Evaluate new forms of radiotherapy delivery.Evaluate new forms of radiotherapy delivery.(brachytherapy, 3-dimensional conformal radiotherapy,(brachytherapy, 3-dimensional conformal radiotherapy,

intensity modulated radiotherapy) (IMRT)intensity modulated radiotherapy) (IMRT)

Test new systemic therapies in conjunction with RTTest new systemic therapies in conjunction with RT(chemotherapy, hormonal treatment, biologic agents and(chemotherapy, hormonal treatment, biologic agents andnew classes of cytostatic, cytotoxic and targeted therapies)new classes of cytostatic, cytotoxic and targeted therapies)

Employ translational research strategies to identify patientEmploy translational research strategies to identify patient subgroups at risk for failure with existing treatments andsubgroups at risk for failure with existing treatments and identify new approaches for these patientsidentify new approaches for these patients

www.rtog.org 7

RTOG STAFFRTOG STAFF

Over 80 RTOG staff membersOver 80 RTOG staff members

AdministrativeAdministrative

Research AssociatesResearch Associates

StatisticiansStatisticians

Quality AssuranceQuality Assurance

Protocol DevelopmentProtocol Development

www.rtog.org 8

ACCOMPLISHMENTSACCOMPLISHMENTS

www.rtog.org 9

CERVIX CANCERCERVIX CANCERRTOG 9001RTOG 9001

• RTOG demonstrated RTOG demonstrated that combining that combining chemotherapy with chemotherapy with pelvic radiation pelvic radiation improves the 5 year improves the 5 year survival rate for women survival rate for women with locally advanced with locally advanced cervix cancer fromcervix cancer from

58% to 73%.58% to 73%.

www.rtog.org 10

LUNG CANCERLUNG CANCERRTOG 9410RTOG 9410

• RTOG FOUND THAT RTOG FOUND THAT HEALTHIER PATIENTS WITH HEALTHIER PATIENTS WITH INOPERABLE NON-SMALL-INOPERABLE NON-SMALL-CELL LUNG CANCER HAD CELL LUNG CANCER HAD BETTER RESULTS IF THEY BETTER RESULTS IF THEY RECEIVED RECEIVED CHEMOTHERAPY DURING CHEMOTHERAPY DURING RADIOTHERAPY RATHER RADIOTHERAPY RATHER THAN PRIOR TO THAN PRIOR TO RADIOTHERAPY.RADIOTHERAPY.

www.rtog.org 11

HEAD AND NECK CANCERSHEAD AND NECK CANCERSRTOG 9003RTOG 9003

• RTOG demonstrated the RTOG demonstrated the superiority of concomitant superiority of concomitant boost radiotherapy and boost radiotherapy and hyperfractionated radiotherapy hyperfractionated radiotherapy for locally advanced squamous-for locally advanced squamous-cell carcinoma.cell carcinoma.

• RTOG demonstrated that RTOG demonstrated that patients who received patients who received chemotherapy together with chemotherapy together with their radiotherapy after surgery their radiotherapy after surgery were far less likely to have a were far less likely to have a recurrence of their cancer.recurrence of their cancer.

www.rtog.org 12

BRAIN CANCERBRAIN CANCERRTOG 9508RTOG 9508

• RTOG improved survival RTOG improved survival more thanmore than

33%33%

for patients with a single for patients with a single brain metastasis by using brain metastasis by using whole brain radiotherapy whole brain radiotherapy followed by stereotactic followed by stereotactic radiosurgery boost instead radiosurgery boost instead of whole brain treatment of whole brain treatment alonealone..

www.rtog.org 13

CNS LYMPHOMACNS LYMPHOMARTOG 9310RTOG 9310

• RTOG improved the median RTOG improved the median survival for patients with survival for patients with non-AIDS-related primary non-AIDS-related primary

CNS lymphoma fromCNS lymphoma from

11.6 11.6 monthsmonths to to

30.4 30.4 monthsmonths

by giving high dose by giving high dose chemotherapy for 10 weeks chemotherapy for 10 weeks prior to RT.prior to RT.

www.rtog.org 14

PROSTATE CANCERPROSTATE CANCERRTOG 8531RTOG 8531

• RTOG found that men who continued on hormonal therapy for at least five years after their treatment for locally advanced prostate cancer, lived longer than men who discontinued the hormones earlier than the five year time point.

www.rtog.org 15

THANK YOU !THANK YOU !